Alnylam Pharmaceuticals (ALNY) has been drawing interest after recent trading, with the share price around $331.24 and mixed short term returns, including a 7 day decline and a positive 1 day move.

That short term pullback, including a 6.6% 30 day share price return decline and a 26.6% 90 day share price return decline, sits against a much stronger backdrop. The 1 year total shareholder return is 39.7% and the 5 year total shareholder return is 141.1%, suggesting momentum has recently faded after a solid multi year run.

If Alnylam’s recent moves have you looking wider across the market, you might like our screener of 29 healthcare AI stocks as another place to find ideas tied to advanced therapies and data driven medicine.

With revenue of US$3.7b, net income of US$313.7m and a share price around US$331, the key question for investors is whether Alnylam is still undervalued or if the market is already fully pricing in its prospects.

Most Popular Narrative: 32.7% Undervalued

Alnylam’s latest close at $331.24 sits well below the most followed narrative fair value of about $491.92, which leans on a detailed long term RNAi growth story.

The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue curve and profit margins are baked into that gap between price and fair value? The narrative leans on brisk top line expansion, rising profitability and a richer future earnings multiple. The exact mix of those levers, and how far they are pushed, is where the real story sits.

Result: Fair Value of $491.92 (UNDERVALUED)

However, those assumptions could be challenged if TTR pricing pressure hits margins, or if heavy R&D and commercial spending outpaces revenue and delays sustained profitability.

Another Angle on Valuation

That 32.7% undervaluation story leans heavily on future growth and margins. Yet on a simple P/E, Alnylam trades at about 140x, versus a fair ratio of 33.6x, the US Biotechs industry at 23x and peers at 17.7x. This signals a much richer price tag. Which lens do you trust more?

Next Steps

If this mix of enthusiasm and doubt feels familiar, use it as a prompt to look at the full picture now and weigh things yourself, including 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one company, you risk missing other opportunities. Take a few minutes to scan wider and pressure test your next move.

• Spot potential bargains fast by sorting through 54 high quality undervalued stocks that pair quality fundamentals with more modest pricing.
• Prioritise resilience first with 80 resilient stocks with low risk scores, focusing on companies that score well on financial strength and risk factors.
• Hunt for fresher opportunities using our screener containing 24 high quality undiscovered gems, where solid businesses are earning attention from fewer investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.